Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines : 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

Autor:	Mutua, Gaudensia, Anzala, Omu, Luhn, Kerstin, Robinson, Cynthia, Bockstal, Viki, Anumendem, Dickson, Douoguih, Macaya
Zdroj:	The Journal of Infectious Diseases, 2019 Jul 01. 220(1), 57-67.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/26674963 Zobrazit plný text záznamu